Dacomitinib, cemiplimab & #oncopharm updates
from OncoPharm Hosted by John Bossaer
Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 27 minutes long.
When was this OncoPharm episode published?
This episode was published on October 4, 2018.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.